ProMIS Neurosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NET LOSS PER SHARE (Tables)

NET LOSS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2023

NET LOSS PER SHARE

Summary of computation of basic and diluted net loss per share attributable to common shareholders


		Three Months Ended September 30,						Nine Months Ended September 30,
		2023			2022			2023			2022
Numerator:
Net loss attributable to common shareholders		$	(2,360,648)		$	(5,956,875)		$	(9,632,053)		$	(10,796,758)
Denominator:
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders, basic and diluted			12,370,830			7,195,529			9,861,719			7,195,529
Net loss per share attributable to common shareholders, basic and diluted		$	0.19		$	0.83		$	0.98		$	1.50

Summary of outstanding potentially dilutive common shares equivalents excluded from the computation of diluted net loss per share


		September 30,
		2023		2022
Options issued and outstanding under stock option plan		1,041,492		689,321
Warrants		13,955,897		1,560,588
Series 1 Convertible Preferred Shares		1,166,667		1,166,667
Deferred Share Units		1,061		1,061
Total		16,165,117		3,417,637